Summary
This study tests treatment for people with early-stage breast cancer that has a high chance of coming back after treatment. It will test adding an immunotherapy drug called durvalumab to usual chemotherapy before surgery. To determine if cancer has a high chance of returning, the trial uses a test called MammaPrint. The MammaPrint test predicts how likely it is the cancer will come back (recur) by looking at many genes in cancer cells. Treatment in the trial is for patients who receive a High 2 result on MammaPrint testing.
Description
This trial is set up to find out:
-If adding durvalumab to the usual chemotherapy before surgery can lower the chance of breast cancer returning
-If adding durvalumab to the usual chemotherapy helps completely get rid of breast cancer
-What side effects people have from adding durvalumab to usual chemotherapy
This trial is for adults, age 18 or older, with stage 2 or 3 breast cancer.
This trial may be for people who:
- Have cancer that is hormone receptor (HR)-positive and HER2-negative